Introduction: The objectives of this study were to evaluate the outcome of nonimmune hydrops fetalis in an attempt to identify independent predictors of perinatal mortality. Material and Methods: A retrospective cohort study was conducted including all cases of nonimmune hydrops from two tertiary care centers. Perinatal outcome was evaluated after classifying nonimmune hydrops into ten etiological groups. We examined the effect of etiology, site of fluid accumulation, and gestational age at delivery on postnatal survival. Neonatal mortality and hospital discharge survival were compared between the expectant management and fetal intervention groups among those with idiopathic etiology. Results: A total of 142 subjects were available for analysis. Generally, nonimmune hydrops carried 37% risk of neonatal mortality and 50% chance of survival to discharge, which varies markedly based on the underlying etiology. Ascites was an independent predictor of perinatal mortality (p value = 0.003). There was nonsignificant difference in neonatal mortality and hospital discharge survival among idiopathic cases that were managed expectantly versus those in whom fetal intervention was carried out. Discussion: The outcome of nonimmune hydrops varies largely according to the underlying etiology and the presence of ascites is an independent risk factor for perinatal mortality. In our series, fetal intervention did not offer survival advantage among fetuses with idiopathic nonimmune hydrops.

1.
Rose C, Bofill J, Le M, Martin R: Non-immune hydrops fetalis: prenatal diagnosis and perinatal outcomes. J Miss State Med Assoc 2005;46:99-102.
2.
Takci S, Gharibzadeh M, Yurdakok M, Ozyuncu O, Korkmaz A, Akcoren Z, Yigit S: Etiology and outcome of hydrops fetalis: report of 62 cases. Pediatr Neonatol 2014;55:108-113.
3.
Skoll M, Sharland G, Allan L: Is the ultrasound definition of fluid collections in non‐immune hydrops fetalis helpful in defining the underlying cause or predicting outcome? Ultrasound Obstet Gynecol 1991;1:309-312.
4.
Bellini C, Hennekam R: Non‐immune hydrops fetalis: a short review of etiology and pathophysiology. Am J Med Genet A 2012;158:597-605.
5.
Abrams ME, Meredith KS, Kinnard P, Clark RH: Hydrops fetalis: a retrospective review of cases reported to a large national database and identification of risk factors associated with death. Pediatrics 2007;120:84-89.
6.
Bellini C, Hennekam R, Fulcheri E, Rutigliani M, Morcaldi G, Boccardo F, Bonioli E: Etiology of nonimmune hydrops fetalis: a systematic review. Am J Med Genet A 2009;149:844-851.
7.
Ota S, Sahara J, Mabuchi A, Yamamoto R, Ishii K, Mitsuda N: Perinatal and one‐year outcomes of non‐immune hydrops fetalis by etiology and age at diagnosis. J Obstet Gynaecol Res 2016;42:385-391.
8.
Yeom W, Paik ES, An J-J, Oh S-y, Choi S-J, Roh C-R, Kim J-H: Clinical characteristics and perinatal outcome of fetal hydrops. Obstet Gynecol Sci 2015;58:90-97.
9.
Hasnani-Samnani Z, Mahmoud MIM, Farid I, Al Naggar E, Ahmed B: Non-immune hydrops: Qatar experience. J Matern Fetal Neonatal Med 2013;26:449-453.
10.
Bellini C, Donarini G, Paladini D, Calevo MG, Bellini T, Ramenghi LA, Hennekam RC: Etiology of non‐immune hydrops fetalis: an update. Am J Med Genet A 2015;167:1082-1088.
11.
Nakayama H, Kukita J, Hikino S, Nakano H, Hara T: Long‐term outcome of 51 liveborn neonates with non‐immune hydrops fetalis. Acta Paediatr 1999;88:24-28.
12.
Smoleniec J, James D: Predictive value of pleural effusions in fetal hydrops. Fetal Diagn Ther 1995;10:95-100.
13.
Cardwell MS: Aspiration of fetal pleural effusions or ascites may improve neonatal resuscitation. South Med J 1996;89:177-178.
14.
Pettersen H, Nicolaides K: Pleural Effusions. Cambridge, Cambridge University Press, 1997, pp 261-272.
15.
Lamont RF, Sobel J, Vaisbuch E, Kusanovic JP, Mazaki‐Tovi S, Kim SK, Uldbjerg N, Romero R: Parvovirus B19 infection in human pregnancy. BJOG 2011;118:175-186.
16.
Aubard Y, Derouineau I, Aubard V, Ronique E, Chalifour V, Preux P-M: Primary fetal hydrothorax: a literature review and proposed antenatal clinical strategy. Fetal Diagn Ther 1999;13:325-333.
17.
Nassr AA, Ruano R, Espinoza J, Shamshirsaz AA: Successful in utero percutaneous fetoscopic release of a wrapped pleuro-amniotic shunt around the fetal arm: case report and review of the literature. Fetal Diagn Ther 2016, DOI: 10.1159/000450606.
18.
Mann S, Johnson MP, Wilson RD: Fetal thoracic and bladder shunts. Semin Fetal Neonatal Med 2010;15:28-33.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.